

OXALIPLATIN FOR THE TREATMENT OF CISPLATIN-RESISTANT CANCER: A SYSTEMATIC REVIEW

Britta Stordal, Nick Pavlakis and Ross Davey*

Bill Walsh Cancer Research Laboratories, Royal North Shore Hospital and University
of Sydney, St Leonards, NSW 2065, AUSTRALIA.

Authors

Miss Britta Stordal

Bill Walsh Cancer Research
Laboratories

Royal North Shore Hospital
St Leonards NSW 2065

AUSTRALIA

Tel: +61-2-9926-7298

Fax: +61-2-9926-5253

email: bstordal@med.usyd.edu.au

Dr Nick Pavlakis

Department of Medical Oncology
Royal North Shore Hospital

St Leonards NSW 2065

AUSTRALIA

Tel: +61-2-9926-5015

Fax: +61-2-9906-4150

email: pavlakis@med.usyd.edu.au

*Corresponding Author:

Adjunct Prof Ross Davey

Bill Walsh Cancer Research Laboratories
Royal North Shore Hospital

St Leonards NSW 2065

AUSTRALIA

Tel: +61-2-9926-7456

Fax: +61-2-9926-5253

email: rdavey@med.usyd.edu.au

Abbreviated Title: Oxaliplatin in Cisplatin-Resistant Cancer

Keywords: Oxaliplatin, Cisplatin, Resistance, Cross Resistance.

OXALIPLATIN FOR THE TREATMENT OF CISPLATIN-RESISTANT CANCER: A SYSTEMATIC REVIEW

Abstract

Oxaliplatin is widely regarded as being active in cisplatin-resistant cancer. We undertook a systematic review of the literature to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with “cisplatin-resistant” cancer. We identified 25 pre-clinical cell models of platinum resistance and 24 clinical trials reporting oxaliplatin based salvage therapy for cisplatin-resistant cancer. The pre-clinical data suggests that there is cross-resistance between cisplatin and oxaliplatin in low-level resistance models. In models with high level resistance (>10 fold) there is less cross resistance between cisplatin and oxaliplatin, which may be a reason why oxaliplatin is thought to be active in cisplatin-resistant cancer. In clinical trials where oxaliplatin has been used as part of salvage therapy for patients who have failed cisplatin or carboplatin combination chemotherapy, there was a much lower response rate in patients with platinum-refractory or resistant cancers compared to platinum-sensitive cancers. This suggests that there may be cross-resistance between cisplatin and oxaliplatin in the clinic. Oxaliplatin as a single agent had a poor response rate in cisplatin refractory and resistant cancer. Oxaliplatin performed better in combination with other agents for the treatment of platinum resistant/refractory cancer suggesting that the benefit of oxaliplatin may lie in its more favourable toxicity and ability to be combined with other drugs rather than an underlying activity in cisplatin resistance. Oxaliplatin therefore should not be considered broadly active in cisplatin-resistant cancer.

Introduction

The anti-proliferative properties of cisplatin were first observed in the 1960s. The first cancer patient received cisplatin in April 1971. Cisplatin quickly progressed through clinical trials becoming the first platinum compound approved for cancer therapy and has been used widely in cancer patients since 1978¹. Cisplatin is used in combination with other drugs to treat a variety of solid tumours and is one of the most successful chemotherapeutics used today. However, for those patients who do not respond to first line treatment or those who relapse with resistant disease, the prognosis is very poor². The past 30 years have seen extensive research into the mechanism of action of cisplatin, the development of new platinum drugs and research into the mechanisms of platinum drug resistance.

Many other platinum drugs have been developed in an attempt to improve on cisplatin. Oxaliplatin is part of the 'dach' family of platinum compounds. This group of platinum compounds were first synthesised in 1972 by substituting the amine radicals of cisplatin with a 'dach' radical³. The prototypes of this group showed promising anti-tumour activity but low solubility in water, limiting their potential use in the clinic. Modifications to improve water solubility were made and oxaliplatin was first synthesised in the late 1970s. Oxaliplatin demonstrated both aqueous solubility and anti-tumour activity⁴. Oxaliplatin was shown to have activity against colon cancer *in vitro*⁴ and is now used as a treatment for colon cancer in combination with 5-fluorouracil^{5,6}. Oxaliplatin is a better tolerated chemotherapeutic than cisplatin, while both cause neurotoxicity, the toxicity of oxaliplatin is more rapidly reversible^{7,8}.

Oxaliplatin has been widely regarded as potentially useful for the treatment of cisplatin-resistant cancer. Numerous clinical trials have been published using oxaliplatin as part of salvage therapy for cisplatin-resistant tumours. The pre-clinical evidence cited by these clinical studies for oxaliplatin's activity in cisplatin-resistant cancer comes in general from studies of highly cisplatin-resistant cell lines with low-level oxaliplatin resistance^{9,10} or review articles summarising these findings and oxaliplatin in general^{11,12}. While highly resistant models are useful to understand the possible mechanisms of resistance, drug resistance in the clinical setting typically

occurs at lower levels of resistance^{13,14} and may therefore involve different mechanisms of resistance.

Other pre-clinical data cited as evidence of oxaliplatin's activity in cisplatin resistant cancer is the differential activity of cisplatin and oxaliplatin in the National Cancer Institute's panel of 60 cell lines^{4,15}. Oxaliplatin shows activity in colon carcinoma whereas cisplatin does not. Although these studies have been used to suggest a different profile of cross resistance between the two compounds, they only demonstrate that colon carcinoma cells are more sensitive to oxaliplatin and do not shed any light on the pattern of cross resistance between the two compounds in resistant cancers or other types of cancer.

Oxaliplatin has been thought to have differing activity to cisplatin due to structural differences between the two molecules, yet both bind to and create adducts in GC rich areas of the DNA strand. There are many mechanisms by which cancer cells acquire resistance to platinum drugs, many of which have been characterised in resistant cell models. Mechanisms of platinum resistance common to both drugs include increased cellular glutathione leading to increased detoxification^{16,17} or decreased accumulation of the drug within the cell^{18,17} yet some models have neither of these mechanisms¹⁹. The activity of oxaliplatin in some cisplatin-resistant cell lines is thought to be due to DNA repair or damage recognition processes that discriminate between cisplatin and oxaliplatin adducts. A loss of mismatch repair increases resistance to cisplatin adducts, but has no effect on oxaliplatin adducts in cell lines²⁰. However, this relationship remains to be confirmed in the clinic where studies show decreases in mismatch repair genes as prognostic of both increased²¹ and decreased survival²² in response to cisplatin based therapy. Mismatch repair genes have not as yet been examined in the clinic in response to oxaliplatin therapy.

We undertook this systematic review to identify, describe and critique the clinical and pre-clinical evidence for the use of oxaliplatin in patients with "cisplatin-resistant" cancer.

Methods

We conducted literature searches for pre-clinical and clinical studies using Medline. Review articles and articles not published in English were excluded. The reference lists in included papers were also searched for additional studies. Conference presentations and abstracts were not included. The literature searches were last updated in October 2006.

Literature searches for pre-clinical studies

Medline was searched for studies describing the cross-resistance between cisplatin and oxaliplatin in platinum-resistant cell lines using 'cisplatin', 'oxaliplatin', 'cross resistance', 'cross resistant', 'resistant', 'resistance' and 'cell line' as keywords. Resistance studies looking at a panel of cancer cell lines and the relative resistance between them were excluded, as these studies examine innate platinum resistance and not resistance developed from chemotherapy. Resistant cell lines resulting from transfection of cells were also excluded. Resistant cell lines developed using multiple drugs were also excluded, as this would introduce other factors to the cross resistance analysis between cisplatin and oxaliplatin. In some cases the same platinum-resistant cell line has been published with cisplatin and oxaliplatin cross resistance data in multiple publications. In this case the key publication has been listed in the table.

Literature searches for clinical studies

Medline was searched for all controlled clinical trials using oxaliplatin alone or in combination as treatment for patients who had previously received cisplatin or carboplatin based chemotherapy. 'Oxaliplatin', 'cisplatin' and 'platinum' were used as keywords and studies were limited to any clinical trial type. Studies using oxaliplatin as first line therapy were excluded. Studies where patients had no prior treatment with cisplatin or carboplatin were excluded. Studies including both cisplatin pre-treated and chemotherapy naïve patients were eligible as long as the results for platinum pre-treated patients were reported separately to allow data extraction.

Cisplatin and oxaliplatin resistance in pre-clinical studies

The cellular models of platinum resistance can be divided into three groups. The first contain cell lines developed from patients before and after chemotherapy^{13,14}. The platinum sensitivity of these paired cell lines is usually determined by exposing them to a range of platinum concentrations and assessing cell viability with either an MTT or clonogenic assay. The IC₅₀ (drug concentration causing 50% growth inhibition) for these paired cell lines can be used to determine the increase in resistance known as fold resistance by the following equation:-

$$\text{Fold Resistance} = \text{IC}_{50} \text{ of Platinum Resistant Cell Line} / \text{IC}_{50} \text{ of Parental Cell Line}$$

These studies have found that drug resistance in this clinical setting typically produces resistance of 2 to 3 fold^{13,14}.

The second group contains those cell lines developed in a clinically relevant way with doses of 1-10 µg/ml as determined by pharmacokinetic studies^{23,24}. The scheduling of treatments may also be important since continuous exposure to drug is likely to produce higher levels of resistance as it does not mimic clinical therapy which is delivered in a pulsed manner with cycles of treatment. The third group contains the highly drug resistant models. Although these are valuable models for studying potential resistance mechanisms, they are less appropriate to study the activity of oxaliplatin at clinical levels of cisplatin resistance.

The literature search for models of acquired platinum resistance which report cross resistance data for both cisplatin and oxaliplatin identified 25 platinum-resistant cell lines (Table 1). The majority of these cell lines are from the third group of cell models with high levels of resistance. The major mechanisms of resistance to platinum for each cell line in Table 1 is also listed. The resistance mechanism was not determined for some of the cell lines listed as most of these studies were aimed at showing a differential activity between cisplatin and oxaliplatin rather than determining the mechanisms of platinum resistance.

Table 1 -Cell Lines With Acquired Platinum Drug Resistance – Fold Resistance Data for Cisplatin and Oxaliplatin

	Cell Line	Cancer	Treatment Dose and Strategy	Cis Fold	Ox Fold	Resistance Mechanism	Reference
Cisplatin	A431/Pt	Cervical	Continuous 0.1 µg/ml – 1 µg/ml	2.6	0.96	↓Acc (Cis), ↓Adducts (Cis), ↓MSH2	25,26
	KB-3-1/KCP4	Epidermoid	Continuous 7 µg/ml	51.3	94.5	↑GSH ↓Acc (Cis), ↑NER, ↓MSH6	16
	H12DDP	Germ Cell	Unknown dose Pulsed exposure over 49 weeks	8.0	2.0	ND	9
	P388/DDP	Leukemia*	Single Dose 6-8 mg/kg	7.0	8.0	ND	27
	L1210/DDP	Leukemia*	Single Dose 6-8 mg/kg	40.0	1.0	↑Replicative bypass of adducts (Cis)	27,28
	PC-9/CDDP	NSCLC	15 months 0.5 µg/ml	18.3	5.1	ND	10
	PC-14/CDDP	NSCLC	15 months 1.5 µg/ml	7.7	2.3	ND	10
	A2780-E(80)	Ovarian	Continuous 0.075 µg/ml -24 µg/ml	92.0	4.7	↓Acc(Cis and Ox)	4
	KB CP(20)	Ovarian	Continuous 0.075 µg/ml - 6 µg/ml	78.0	2.7	↓Acc(Cis and Ox)	4
	A2780/CP	Ovarian	Unclear from previous literature	10.9	2.0	↓Acc(Cis and Ox), ↑DNA Repair	29
	SKOV3-cis	Ovarian	Continuous stepwise to 20 µg/ml	4.0	5.3	↓Acc(Cis), ↓P-gp	18
	A2780-cis	Ovarian	Continuous stepwise to 20 µg/ml	3.0	20.0	↓Acc(Cis), ↑P-gp	18
	H69CIS200	SCLC	8 4-day pulses 0.2 µg/ml	1.7	1.6	No change GSH or Acc	19
	(SCLC1)SR-2	SCLC	5 ng/ml 24 hour pulses then continuous 0.1 µg/ml	16.0	1.0	Increase in mutated MRP4	30
Oxaliplatin	HCT116/R1	Colon	Continuous stepwise to 1.99 µg/ml	2.1	27.8	ND	31
	HCT116/R2	Colon	Continuous stepwise to 4 µg/ml	2.9	68.4	↓ pro-apoptotic Bax	31
	HCT116oxaliR	Colon	Pulsed 0.051 – 0.103 µg/ml	0.8	15.8	No change GSH or Pt Acc	32
	HT29oxaliR	Colon	Pulsed 0.131 – 0.262 µg/ml	0.6	13.3	No change GSH or Pt Acc	32
	A2780/C25	Ovarian	Continuous 0.04 µg/ml – 9.93 µg/ml	5.1	8.4	↓Acc (Cis and Ox), ↑GSH	29,17
	CH1oxaliR	Ovarian	Pulsed 0.079 – 0.159 µg/ml	3.9	3.0	No change GSH or Pt Acc	32
	A2780/C10	Ovarian	Continuous 0.04 µg/ml – 3.97 µg/ml	3.0	18.0	↑GSH	33,17
	A2780oxaliR	Ovarian	Pulsed 0.030-0.060 µg/ml	1.2	3.7	No change GSH or Pt Acc	32
Carboplatin	H69OX400	SCLC	8 4-day pulses 0.4 µg/ml	1.8	1.8	No change GSH or Acc	19
	SKOV3-car	Ovarian	Continuous stepwise to 100 µg/ml	1.5	4.0	↓Accumulation(Car), ↓P-gp	18
	A2780-car	Ovarian	Continuous stepwise to 100 µg/ml	4.0	12.5	↓Acc(Car), ↑P-gp	18

Acc – accumulation, Car – carboplatin, Cis – cisplatin, GSH – glutathione, ND – Not Determined, NER – nucleotide excision repair, NSCLC – non-small cell lung cancer, MRP4 – multidrug resistance associated protein 4, Ox – oxaliplatin, P-gp – P-glycoprotein, Pt – Platinum, Tax - taxol. * Murine cells.

For each cell line in Table 1 the fold oxaliplatin resistance was plotted against the fold cisplatin resistance, allowing an analysis of the pattern of cross resistance between the two compounds (Figure 1). The definition of cross resistance is a matter of debate in the literature. Some studies consider two drugs cross-resistant only if a similar level of resistance is observed. For the purposes of this review we have defined cross resistance between cisplatin and oxaliplatin as greater than or equal to 2-fold resistance to both drugs. This definition is therefore based on what would be clinically observed as cross resistance.

Figure 1 shows that the majority of models of acquired platinum resistance are cross-resistant to both cisplatin and oxaliplatin having at least 2-fold resistance to both drugs. The lower level resistant models, below 10-fold, tend to be cross-resistant to a similar level to both drugs. However, the higher level resistant models, above 10-fold indicated by grey shading, are highly resistant to their selecting drug and then exhibit a lower level of resistance to the other drug. This suggests that a common mechanism of low-level resistance to both cisplatin and oxaliplatin develops at clinical levels of drug treatment. Whereas the resistance mechanisms that develop at higher drug concentrations are likely to be more specific for the selecting drug. Figure 1 also shows that there is a limited number of clinically relevant models of cisplatin and oxaliplatin resistance, as most are well in excess of 2 to 3-fold.

The cited evidence for the activity of oxaliplatin in cisplatin-resistant cancers comes from highly cisplatin-resistant cell models, where there is above 10-fold resistance to cisplatin and below 10-fold resistance to oxaliplatin ^{4,29,10} (indicated in grey in Figure 1). However Figure 1 shows that the reverse is also true; where there is greater than 10-fold resistance to oxaliplatin there is less than 10-fold resistance to cisplatin ^{33,18}. This suggests that in high level drug resistance to either cisplatin or oxaliplatin there will be limited activity to the other drug. Furthermore, if the same degree of cross resistance occurred at high and low drug concentrations it is likely that more than one highly cross resistant cell line would have been found in the systematic review process. The only highly cross resistant cell line found was the KB-3-1/KCP4 cells which were 51.3-fold resistant to cisplatin and 94.5-fold resistant to oxaliplatin ¹⁶.

Interestingly, two oxaliplatin-resistant colon carcinoma cell lines HCT116oxaliR and HT29oxaliR, shown in Figure 1, have become hypersensitive to cisplatin with a fold resistance for cisplatin of less than 1³². This finding may relate to oxaliplatin's unique activity in colon carcinoma⁴; however, this hypersensitivity is not the case in all oxaliplatin resistant colon carcinomas found in the systematic review as HCT116/R1 and HCT116/R2 show low-level cisplatin resistance³¹. This suggests that cisplatin may have activity in oxaliplatin-resistant colon cancer. Further studies could be undertaken to examine this, although the clinical utility of cisplatin following oxaliplatin is likely to be low, due to cisplatin's neurotoxicity³⁴.

Oxaliplatin shows a lower level of cross resistance in the majority of highly cisplatin-resistant cells (Figure 1). This does not represent an increase in activity in cisplatin resistance as this would be demonstrated by cell lines becoming hypersensitive to oxaliplatin which was not the case in the vast majority of cell lines found. Cisplatin and oxaliplatin-resistant cell lines are often hypersensitive to other non-platinum containing chemotherapeutics such as paclitaxel and taxotere^{19,35}. Paclitaxel has also shown promising results in the treatment of patients resistant to cisplatin^{36,37,38}. Therefore, paclitaxel and taxotere appear to have increased activity in platinum-resistant cancer, although the mechanism of this activity is not fully understood. This is quite different to the pattern observed for the activity of oxaliplatin in cisplatin-resistant cells.

Oxaliplatin in the treatment of patients with cisplatin-resistant cancers

Oxaliplatin has been used as a single agent and in combination with other chemotherapeutics for the treatment of cancers that are unresponsive to cisplatin or carboplatin based combination chemotherapy. Clinical platinum resistance is variably defined in the clinic and as such it is difficult to make comparisons of treatment activity between trials. The definition of platinum resistance is more critical in highly platinum sensitive diseases such as ovarian and testicular cancer. Many trialists define primary platinum resistance as disease progression during first-line treatment with a platinum containing regimen. However there is less agreement for secondary platinum resistance or potentially platinum sensitive patients, where it is common to use a platinum free interval, e.g. At least 6 months, to try to define patients as "potentially

sensitive”. Markman³⁹ describes a classification system to assist patient selection in second-line ovarian cancer studies. The relevance of this system to other cancers is however dependent on the innate platinum sensitivity of the underlying tumour type.

Cisplatin combination chemotherapy is the cornerstone of treatment of ovarian and testicular carcinomas. Testicular carcinomas are exquisitely sensitive to cisplatin which cures > 80% of patients, however when resistance does occur the prognosis is usually poor⁴⁰. Similarly initial platinum responsiveness in ovarian cancer is high, but 80% of patients will eventually relapse and be cisplatin resistant⁴¹.

Interpreting drug activity after platinum treatment even in these two highly platinum sensitive cancer types is further complicated by the common use of platinum in combination with other agents. Here, resistance to combination chemotherapy involves more than just resistance to platinum agents and the response to second line platinum containing regimens is influenced by the non-platinum agents used in both first and second line therapy.

In our search of the literature for published controlled clinical trials describing the activity of oxaliplatin either as a single agent or in combination in the treatment of patients having previously received cisplatin based combination chemotherapy, we identified 24 studies. Using Markman’s criteria as a template, the patients within these studies were classified into five groups according to the following definitions.

- A) Platinum Refractory – Progression of disease or failure to achieve a partial response during last platinum based combination chemotherapy.
- B) Platinum Resistant – Progression of disease within 6 months after platinum based combination chemotherapy.
- C) Platinum Sensitive – Progression of disease greater than 6 months after platinum based combination chemotherapy.
- D) Non-Platinum Refractory – Patients who do not progress during platinum therapy but their individual time of disease progression after platinum treatment is not itemised in the study. These patients can therefore not be classified as platinum resistant (B) or platinum sensitive (C).

E) Unclassified – Patients who had been previously treated with platinum chemotherapy but where there was not enough information to classify in A, B, C or D.

Tables 2 and 3 summarise the results on patients from clinical trials which have used oxaliplatin as a single agent and in combination respectively for the treatment of patients who have previously received cisplatin or carboplatin based chemotherapy. Patients from each study have been categorised as group A-E according to the above definitions. The pooled response rate (RR) of patients grouped by their platinum resistance status in 460 ovarian and 75 testicular cancer patients is presented in Figure 2. Other cancer types found in the systematic review included, bladder, cervical, gastric, mesothelioma and NSCLC. However, only one study was found for each of these cancer types.

Table 2 – Single agent oxaliplatin in platinum pre-treated cancer

Cancer	Treatment Regimen	Respondents	Study Criteria for Platinum Resistance	Reference
Bladder	Oxaliplatin 130 mg/m ² every 21 days	B) 0/8 platinum resistant C) 1/10 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen	¹⁵
Cervical	Oxaliplatin 130 mg/m ² every 21 days	B) 0/15 platinum resistant C) 2/9 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen	⁴²
Ovarian	Oxaliplatin 130 mg/m ² every 21 days	B)1/23 platinum resistant	Resistance defined as progressive disease within 6 months of a platinum regimen	⁴³
Ovarian	Oxaliplatin 130 mg/m ² every 21 days	A) 1/18 platinum refractory C) 10/16 platinum sensitive D) 0/8 non-platinum refractory	Resistance defined by Markman's Criteria	⁴¹
Ovarian	Oxaliplatin 130 mg/m ² every 21 days	B) 2/32 platinum resistant C) 5/13 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen	⁴⁴
Ovarian	Oxaliplatin median dose of 100 mg/m ² every 21 days	A) 3/18 platinum refractory D) 6/13 non-platinum refractory	Resistance defined by Markman's Criteria	⁴⁵
Testicular	Oxaliplatin 130 mg/m ² every 14 days or 60 mg/m ² every 7 days for 3 cycles	A) 0/7 platinum refractory B) 6/20 platinum resistant E) 0/5 unclassified	Resistance defined as progressive disease within 4 weeks of a platinum regimen or absolute defined as failure during therapy	⁴⁶

Table 3 - Oxaliplatin combination chemotherapy in platinum pre-treated cancer

Cancer	Treatment Regimen	Respondents	Study Criteria for Platinum Resistance/Sensitivity	Reference
Gastric	Oxaliplatin 85mg/m ² and 5-FU 400 mg/m ² Day 1 and Leucovorin 150 mg/m ² and 2.4-3 g/m ² Day 3 every 14 days	A) 6/20 platinum refractory D) 0/6 non-platinum refractory	Resistance defined as progression during platinum therapy	⁴⁷
Mesothelioma	Oxaliplatin 130 mg/m ² and Raltitrexed 3 mg/m ² every 21 days	E) 3/15 Unclassified	Not defined by study	⁴⁸
Ovarian	Oxaliplatin 130 mg/m ² and Cisplatin 100 mg/m ² every 21 days	A) 3/13 Platinum refractory D) 7/12 non-platinum refractory	Resistance defined by Markman's Criteria	⁴⁹
Ovarian	Taxol 135 mg/m ² Day 1, Oxaliplatin 100 mg/m ² and Cisplatin 75 mg/m ² Day 2, CGSF 5µg/kg/d Days 6-13 every 21 days	C) 6/7 platinum sensitive	Sensitivity defined as > 12 months with progression free disease	⁵⁰
Ovarian	Oxaliplatin 85 mg/m ² , 5-FU 400 mg/m ² and Leucovorin 200 mg/m ² Day1 and 5-FU 600 mg/m ² infusion Day 1 and 2 every 21 days	B) 11/38 platinum resistant	Resistance defined as progressive disease within 6 months of a platinum regimen	⁵¹
Ovarian	Oxaliplatin 100-130 mg/m ² and Taxol 135-175 mg/m ² every 21-28 days	A) 6/18 platinum refractory D) 9/13 non-platinum refractory	Resistance defined by Markman's Criteria	⁵²
Ovarian	Oxaliplatin 130 mg/m ² and Taxol 175 mg/m ² every 21 days	C) 79/98 platinum sensitive	Sensitivity defined as 6 months with progression free disease	⁵³
Ovarian	Oxaliplatin 70 mg/m ² and Liposomal Doxorubicin 30-35 mg/m ² every 28 days	B) 4/14 platinum resistant C) 18/27 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen	⁵⁴
Ovarian	Oxaliplatin 85 mg/m ² Day 1, 5-FU 370 mg/m ² and Leucovorin 30 mg/m ² Days 1 and 8 – repeated every 14 days	A) 0/2 platinum refractory B) 3/12 platinum resistant C) 3/6 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen. Refractory defined as progression during platinum therapy	⁵⁵
Ovarian	Oxaliplatin 85 mg/m ² , Liposomal Doxorubicin 30 mg/m ² and Cyclophosphamide 750 mg/m ² every 21 days	B) 10/27 platinum resistant C) 8/12 platinum sensitive	Resistance defined as progressive disease within 6 months of a platinum regimen.	⁵⁶
Ovarian	Oxaliplatin 85 mg/m ² Day 1 and Gemcitabine 1000 mg/m ² Day 1 and 8 every 21 days	A) 0/3 platinum refractory B) 5/17 platinum resistant	Resistance defined as progressive disease within 6 months of a platinum regimen. Refractory defined as progression during platinum therapy	⁵⁷
Ovarian and NSCLC	Oxaliplatin 70-100 mg/m ² and Gemcitabine 800-1500 mg/m ² every 14 days	B) 3/4 platinum resistant	Resistance defined as progressive disease within 6 months of a platinum regimen	⁵⁸
Testicular	Oxaliplatin 85 mg/m ² Day 1 and Gemcitabine	B) 9/28 platinum resistant	Resistance defined as progressive disease within	⁵⁹

	1000 mg/m ² Day 1 and 8 every 21 days		4 weeks of a platinum regimen	
Testicular	Oxaliplatin 85 mg/m ² Day 1 and Gemcitabine 1000 mg/m ² Day 1 and 8 every 21 days	A) 2/9 platinum refractory B) 5/13 platinum resistant D) 9/13 non-platinum refractory	Resistance defined as progressive disease within 4 weeks of a platinum regimen or absolute defined as failure during therapy	⁶⁰
Testicular	Oxaliplatin 85 mg/m ² Days 1 and 15, Irinotecan 80 mg/m ² Days 1, 8 and 15, prophylactic GCSF Days 3-6, 10-13 and 20-25 every 28 days	E) 7/18 unclassified	Defined as failure to achieve a durable CR to a cisplatin-based regimen time to progression not itemised	⁶¹
Testicular	Oxaliplatin 130 mg/m ² and Cisplatin 100 mg/m ² every 21-28 days with up to four other drugs in combination	A) 4/9 platinum refractory B) 0/1 platinum resistant C) 2/2 platinum sensitive	Resistance defined as progressive disease during last platinum based regimen	⁶²
Testicular	Oxaliplatin 80 mg/m ² , Taxol 70 mg/m ² and Gemcitabine 800 mg/m ² Days 1, 8 and 15 every 28 days	E) 1/7 unclassified	Failure to respond to a platinum containing regimen time to progression not itemised	⁶³

The pooled RR for single agent oxaliplatin in platinum refractory (n = 36, RR 11%) and platinum-resistant (n = 55, RR 5.5 %) ovarian cancer patients was similarly low (Figure 2i). However, the pooled RR was much higher for platinum-sensitive ovarian cancer patients (n = 29, RR = 51.7%). This observation suggests that in ovarian cancer, oxaliplatin as a single agent is not significantly active in cisplatin-resistant or refractory patients. Interpretation of the higher RR in the non-platinum refractory classification (n = 21, RR 28.6%) is confounded by the potential for misclassification of platinum-resistant versus platinum-sensitive patients due to lack of detail in the studies from which their data was extracted. However, the RR of the non-platinum refractory patients is higher than the platinum refractory patients. The RR of the non-platinum refractory patients also falls between the RR for platinum-resistant and platinum-sensitive groups suggesting that there is a mixture of both groups of patients in this cohort.

Figure 2i shows that oxaliplatin when used in combination achieves a higher response rate in all four groups of ovarian cancer patients than when used as a single agent. The pooled response rate of the platinum resistant (n = 108, RR = 30.55%) and refractory patients (n = 36, RR 25.0%) is similar and much lower than the platinum-sensitive patients (n=150, RR 76.0%). In the highly platinum-sensitive testicular cancers (Figure 2ii), the pooled RR for oxaliplatin combination chemotherapy was the same for platinum-refractory patients (n = 18, RR 33.3%), and platinum-resistant patients (n = 42, RR 33.3%). The response rate of platinum sensitive (n = 2, RR = 100%) and non-platinum refractory testicular cancers (n = 13, RR 69.2%) was higher but should be viewed with caution considering the low numbers of patients in these groups. In both ovarian and testicular cancer patients, the pooled RR was higher for platinum sensitive than platinum resistant or refractory patients. This suggests that oxaliplatin has less activity in cisplatin-resistant cancers.

It is difficult to determine whether oxaliplatin alone or the combination of another drug with oxaliplatin is responsible for the response seen in cisplatin pre-treated patients. This question is unlikely to be resolved by further clinical trials as oxaliplatin used in combination therapy is associated with a greater response rate (Figure 2i). From the summary of cellular models of platinum resistance (Figure 1) and clinical trials of oxaliplatin as a single agent (Table 2), it appears that oxaliplatin alone lacks

sufficient activity to overcome cisplatin resistance. However, clinical trials demonstrating a response using oxaliplatin combination therapy in platinum-resistant patients often credit oxaliplatin's lack of cross resistance for the success of treatment^{59,61}. The observed benefit from oxaliplatin combination regimens may well be due to the activity of the other agent or synergy between the two agents, rather than any innate ability for oxaliplatin to overcome cisplatin resistance. Furthermore, the more favourable toxicity profile of oxaliplatin lends itself for use in second-line combination regimens more readily than does cisplatin, and as such, cisplatin is not readily evaluated in this setting, even if it might be similarly active.

There are many different mechanisms of platinum resistance as illustrated by the cell models in Table 1. Perhaps when the particular mechanism of cisplatin resistance in a relapsed patient can be diagnosed, such as the loss of mismatch repair where oxaliplatin shows differential activity to cisplatin²⁰, the most appropriate platinum agent for a patient could be selected. This review highlights that oxaliplatin is not active in all types of cisplatin resistance. The ability to stratify cisplatin-resistant patients as potentially oxaliplatin sensitive based on specific markers of resistance within the tumour, will lead to an improved response rate of oxaliplatin in a subgroup of patients. However, there is a need to examine the role of other non-platinum chemotherapeutics in the treatment of cisplatin-resistant cancers to combat the multiple forms of resistance. Future trials of oxaliplatin in cisplatin-resistant cancers should also integrate the study of markers of platinum resistance within the resistant tumour such as ERCC1, MSH2, MLH1, glutathione and platinum uptake to begin the shift to tailoring salvage chemotherapy to individual mechanisms of resistance. This would be similar to, and complement the pharmacogenomic approach examining germline polymorphisms in genes associated with platinum resistance with the response to firstline chemotherapy⁶⁴.

Conclusions

The conclusion that oxaliplatin is active in cisplatin-resistant cancer has in general been overstated in the literature. Oxaliplatin has some activity in highly cisplatin-resistant cell lines however cisplatin has as much activity in highly-oxaliplatin resistant cell lines. The evidence from low-level platinum resistant cell lines and the

response of patients with cisplatin-resistant cancers suggest that there is cross-resistance between cisplatin and oxaliplatin. Oxaliplatin is useful for the treatment of some cisplatin-resistant cancers when used in combination with other agents. The clinical benefit of oxaliplatin for the treatment of cisplatin-resistant cancer may lie with its more preferable toxicity profile, which allows successful combination with other agents rather than any greater activity in cisplatin-resistance.

References

1. Lebwohl, D. and Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. 1998; *European Journal of Cancer* **34**:1522-1534.
2. Kollmannsberger, C., Mayer F., Kuczyk M., Kanz L., and Bokemeyer C. Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. 2001; *World Journal of Urology* **19**:120-125.
3. Chaney, S.G., Campbell S.L., Temple B., Bassett E., Wu Y., and Faldu M. Protein interactions with platinum-DNA adducts: from structure to function. 2004; *Journal of Inorganic Biochemistry* **98**:1551-1559.
4. Rixe, O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., and Fojo T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. 1996; *Biochemical Pharmacology* **52**:1855-1865.
5. Ibrahim, A., Hirschfeld S., Cohen M.H., Griebel D.J., Williams G.A., and Pazdur R. FDA drug approval summaries: oxaliplatin. 2004; *Oncologist*. **9**:8-12.
6. Culy, C.R., Clemett D., and Wiseman L.R. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. 2000; *Drugs* **60**:895-924.
7. Grothey, A. Clinical management of oxaliplatin-associated neurotoxicity. 2005; *Clinical Colorectal Cancer* **5 Suppl 1**:S38-S46.
8. Grothey, A. Oxaliplatin-safety profile: Neurotoxicity. 2003; *Seminars in Oncology* **30**:5-13.
9. Dunn, T.A., Schmoll H.J., Grunwald V., Bokemeyer C., and Casper J. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. 1997; *Investigational New Drugs* **15**:109-114.
10. Fukuda, M., Ohe Y., Kanzawa F., Oka M., Hara K., and Saijo N. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin. 1995; *Anticancer Research* **15**:393-398.
11. Mani, S., Graham M.A., Bregman D.B., Ivy P., and Chaney S.G. Oxaliplatin: a review of evolving concepts. 2002; *Cancer Investigation* **20**:246-263.
12. Raymond, E., Chaney S.G., Taamma A., and Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. 1998; *Annals of Oncology* **9**:1053-1071.
13. Kawai, H., Kiura K., Tabata M., Yoshino T., Takata I., Hiraki A., Chikamori K., Ueoka H., Tanimoto M., and Harada M. Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. 2002; *Lung Cancer* **35**:305-314.

14. Kuroda,H., Sugimoto T., Ueda K., Tsuchida S., Horii Y., Inazawa J., Sato K., and Sawada T. Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. 1991; *International.Journal of Cancer* **47**:732-737.
15. Winqvist,E., Vokes E., Moore M.J., Schumm L.P., Hoving K., and Stadler W.M. A Phase II study of oxaliplatin in urothelial cancer. 2005; *Urologic.Oncology* **23**:150-154.
16. Mukai,M., Kanzaki A., Chen Z.S., Miyashita H., Sumizawa T., Furukawa T., Haraguchi M., Takebayashi Y., Takamatsu H., and Akiyama S. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells. 2002; *Oncology Reports*. **9**:839-844.
17. El-akawi,Z., Abu-hadid M., Perez R., Glavy J., Zdanowicz J., Creaven P.J., and Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. 1996; *Cancer Letters*. **105**:5-14.
18. Li,L., Luan Y., Wang G., Tang B., Li D., Zhang W., Li X., Zhao J., Ding H., Reed E., and Li Q.Q. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma. 2004; *International.Journal of Molecular Medicine* **14**:257-264.
19. Stordal,B.K., Davey M.W., and Davey R.A. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. 2006; *Cancer Chemotherapy & Pharmacology* **58**:256-265.
20. Chaney,S.G., Campbell S.L., Bassett E., and Wu Y. Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. 2005; *Critical.Reviews.in Oncology-Hematology*. **53** :3-11.
21. Scartozzi,M., De Nictolis M., Galizia E., Carassai P., Bianchi F., Berardi R., Gesuita R., Piga A., Cellerino R., and Porfiri E. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. 2003; *European Journal of Cancer* **39**:1144-1149.
22. Kishi,K., Doki Y., Yano M., Yasuda T., Fujiwara Y., Takiguchi S., Kim S., Higuchi I., and Monden M. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers. 2003; *Clinical Cancer Research* **9**:4368-4375.
23. Sockalingam,R., Filippich L., Charles B., and Murdoch B. Cisplatin-induced ototoxicity and pharmacokinetics: preliminary findings in a dog model. 2002; *Annals.of Otology., Rhinology & Laryngology*. **111**:745-750.
24. Liu,J., Kraut E., Bender J., Brooks R., Balcerzak S., Grever M., Stanley H., D'Ambrosio S., Gibson-D'Ambrosio R., and Chan K.K. Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. 2002; *Cancer Chemotherapy & Pharmacology* **49**:367-374.
25. Martelli,L., Di Mario F., Ragazzi E., Apostoli P., Leone R., Perego P., and Fumagalli G. Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive

and cisplatin-resistant human cervical tumour cells. 2006; *Biochemical Pharmacology* **72**:693-700.

26. Lanzi, C., Perego P., Supino R., Romanelli S., Pensa T., Carenini N., Viano I., Colangelo D., Leone R., Apostoli P., Cassinelli G., Gambetta R.A., and Zunino F. Decreased drug accumulation and increased tolerance to DNA damage in tumor cells with a low level of cisplatin resistance. 1998; *Biochemical Pharmacology* **55**:1247-1254.

27. Tashiro, T., Kawada Y., Sakurai Y., and Kidani Y. Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): new experimental data. 1989; *Biomedicine & Pharmacotherapy* **43**:251-260.

28. Gibbons, G.R., Kaufmann W.K., and Chaney S.G. Role of DNA replication in carrier-ligand-specific resistance to platinum compounds in L1210 cells. 1991; *Carcinogenesis* **12**:2253-2257.

29. Hector, S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., and Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. 2001; *Cancer Chemotherapy & Pharmacology* **48**:398-406.

30. Savaraj, N., Wu C., Wangpaichitr M., Kuo M.T., Lampidis T., Robles C., Furst A.J., and Feun L. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. 2003; *International Journal of Oncology* **23**:173-179.

31. Gourdiere, I., Del Rio M., Crabbe L., Candeil L., Copois V., Ychou M., Auffray C., Martineau P., Mechti N., Pommier Y., and Pau B. Drug specific resistance to oxaliplatin is associated with apoptosis defect in a cellular model of colon carcinoma. 2002; *FEBS Letters* **529**:232-236.

32. Sharp, S.Y., O'Neill C.F., Rogers P., Boxall F.E., and Kelland L.R. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. 2002; *European Journal of Cancer* **38**:2309-2315.

33. Varma, R.R., Hector S.M., Clark K., Greco W.R., Hawthorn L., and Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. 2005; *Oncology Reports* **14**:925-932.

34. Rabik, C.A. and Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. 2006; *Cancer Treatment Reviews* **In Press**, **Corrected Proof**: doi:10.1016/j.ctrv.2006.09.006

35. Yamamoto, K., Kikuchi Y., Kudoh K., and Nagata I. Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. [erratum appears in *J Cancer Res Clin Oncol* 2001 Feb;127(2):142]. 2000; *Journal of Cancer Research & Clinical Oncology* **126**:168-172.

36. Gore, M.E., Preston N., A'Hern R.P., Hill C., Mitchell P., Chang J., and Nicolson M. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. 1995; *British Journal of Cancer* **71**:1308-1310.

37. Motzer,R.J. Paclitaxel in salvage therapy for germ cell tumors. 1997; Seminars.in Oncology **24**:S15-S15.
38. Ezcurdia,L., Jovtis S.L., Mickiewicz E., Temperley G., Rondinon M., Blajman C., Coppola F.S., Lewi D., Cazap E., Breier S., Fauce H., Fein L., Polera J., Triguboff E., Uranga G., Pascon G., Luchina A.M., Martinez C.A., Politi P.M., Rubio G., and Alvarez A.M. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group. 1997; Seminars.in Oncology **24**:S15-S15.
39. Markman,M. and Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. 1992; Journal of Clinical.Oncology **10**:513-514.
40. Bokemeyer,C., Kollmannsberger C., Harstrick A., Beyer J., Gerl A., Casper J., Metzner B., Hartmann J.T., Schmoll H.J., and Kanz L. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG). 1999; International.Journal of Cancer **83**:848-851.
41. Dieras,V., Bougnoux P., Petit T., Chollet P., Beuzeboc P., Borel C., Husseini F., Goupil A., Kerbrat P., Misset J.L., Bensmaine M.A., Tabah-Fisch I., and Pouillart P. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. 2002; Annals.of Oncology **13**:258-266.
42. Fracasso,P.M., Blessing J.A., Wolf J., Rocereto T.F., Berek J.S., and Waggoner S. Phase II evaluation of oxaliplatin in previously treated squamous cell carcinoma of the cervix: a gynecologic oncology group study. 2003; Gynecologic.Oncology **90**:177-180.
43. Fracasso,P.M., Blessing J.A., Morgan M.A., Sood A.K., and Hoffman J.S. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study. 2003; Journal of Clinical.Oncology **21**:2856-2859.
44. Piccart,M.J., Green J.A., Lacave A.J., Reed N., Vergote I., Benedetti-Panici P., Bonetti A., Kristeller-Tome V., Fernandez C.M., Curran D., Van Glabbeke M., Lacombe D., Pinel M.C., and Pecorelli S. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. 2000; Journal of Clinical.Oncology **18**:1193-1202.
45. Chollet,P., Bensmaine M.A., Brienza S., Deloche C., Cure H., Caillet H., and Cvitkovic E. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. 1996; Annals.of Oncology **7**:1065-1070.
46. Kollmannsberger,C., Rick O., Derigs H.G., Schleucher N., Schoffski P., Beyer J., Schoch R., Sayer H.G., Gerl A., Kuczyk M., Spott C., Kanz L., and Bokemeyer C. Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. 2002; Journal of Clinical.Oncology **20**:2031-2037.

47. Kim,D.Y., Kim J.H., Lee S.H., Kim T.Y., Heo D.S., Bang Y.J., and Kim N.K. Phase II study of oxaliplatin, 5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer. 2003; *Annals.of Oncology* **14**:383-387.
48. Fizazi,K., Doubre H., Le Chevalier T., Riviere A., Viala J., Daniel C., Robert L., Barthelemy P., Fandi A., and Ruffie P. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. 2003; *Journal of Clinical Oncology* **21**:349-354.
49. Soulie,P., Bensmaine A., Garrino C., Chollet P., Brain E., Fereres M., Jasmin C., Musset M., Misset J.L., and Cvitkovic E. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. 1997; *European.Journal of Cancer* **33**:1400-1406.
50. Delaloge,S., Laadem A., Taamma A., Chouaki N., Cvitkovic E., Pautier P., Misset J.L., and Lhomme C. Pilot study of the paclitaxel, oxaliplatin, and cisplatin combination in patients with advanced/recurrent ovarian cancer. 2000; *American.Journal of Clinical Oncology* **23**:569-574.
51. Pectasides,D., Pectasides M., Farmakis D., Gaglia A., Koumarianou A., Nikolaou M., Koumpou M., Kountourakis P., Papaxoinis G., Mitrou P., Economopoulos T., and Raptis S.A. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase II study. 2004; *Gynecologic.Oncology* **95**:165-172.
52. Faivre,S., Kalla S., Cvitkovic E., Bourdon O., Hauteville D., Dourte L.M., Bensmaine M.A., Itzhaki M., Marty M., and Extra J.M. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience. 1999; *Annals.of Oncology* **10**:1125-1128.
53. Viens,P., Petit T., Yovine A., Bougnoux P., Deplanque G., Cottu P.H., Delva R., Lotz J.P., Belle S.V., Extra J.M., and Cvitkovic E. A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. 2006; *Annals.of Oncology* **17**:429-436.
54. Nicoletto,M.O., Falci C., Pinalto D., Artioli G., Azzoni P., De Masi G., Ferrazzi E., Perin A., Donach M., and Zoli W. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. 2006; *Gynecologic.Oncology* **100**:318-323.
55. Sundar,S., Symonds R.P., Decatris M.P., Kumar D.M., Osman A., Vasanthan S., and O'byrne K.J. Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. 2004; *Gynecologic.Oncology* **94**:502-508.
56. Valerio,M.R., Tagliaferri P., Raspagliesi F., Fulfaro F., Badalamenti G., Arcara C., Cicero G., Russo A., Venuta S., Guarneri G., and Gebbia N. A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma. 2006; *International.Journal of Gynecological.Cancer* **16 Suppl 1**:79-85.

57. Raspagliesi, F., Zanaboni F., Vecchione F., Hanozet F., Scollo P., Ditto A., Grijuela B., Fontanelli R., Solima E., Spatti G., Scibilia G., and Kusamura S. Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane. 2004; *Oncology* **67**:376-381.
58. Faivre, S., Le Chevalier T., Monnerat C., Lokiec F., Novello S., Taieb J., Pautier P., Lhomme C., Ruffie P., Kayitalire L., Armand J.P., and Raymond E. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. 2002; *Annals of Oncology* **13**:1479-1489.
59. Pectasides, D., Pectasides M., Farmakis D., Aravantinos G., Nikolaou M., Koumpou M., Gaglia A., Kostopoulou V., Mylonakis N., and Skarlos D. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. 2004; *Annals of Oncology* **15**:493-497.
60. Kollmannsberger, C., Beyer J., Liersch R., Schoeffski P., Metzner B., Hartmann J.T., Rick O., Stengele K., Hohloch K., Spott C., Kanz L., and Bokemeyer C. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. 2004; *Journal of Clinical Oncology* **22**:108-114.
61. Pectasides, D., Pectasides M., Farmakis D., Aravantinos G., Nikolaou M., Koumpou M., Gaglia A., Kostopoulou V., Mylonakis N., Economopoulos T., and Raptis S.A. Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. 2004; *European Urology* **46**:216-221.
62. Soulie, P., Garrino C., Bensmaine M.A., Bekradda M., Brain E., Di Palma M., Goupil A., Misset J.L., and Cvitkovic E. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients. 1999; *Journal of Cancer Research & Clinical Oncology* **125**:707-711.
63. De Giorgi, U., Rosti G., Aieta M., Fochess, i F., Paoluzz, L., Valduga, ., Marango, and M. Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. 2004; *American Journal of Clinical Oncology* **27**:457-460.
64. Kweekel, D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. 2005; *Cancer Treatment Reviews* **31**:90-105.




Figure 1 – Cross resistance between cisplatin and oxaliplatin in cell models of acquired platinum resistance. The fold resistance of cisplatin and oxaliplatin of each resistant cell line it was derived from is plotted (from Table 1). Cells developed with cisplatin (■), oxaliplatin (▲) and carboplatin (●) are indicated. The dotted line (...) at 1 indicates the fold resistance of the parental cell lines. The dashed line (---) at 2 indicates the level of clinical platinum resistance.




Figure 2 – Response rate of platinum pre-treated patients to oxaliplatin divided by resistance status. The pooled results for i) ovarian cancer and ii) testicular cancer are divided up into four patient groups A) Platinum refractory B) Platinum resistant C) Platinum sensitive and D) Non-platinum Refractory. The open bars are patients who received oxaliplatin as single agent (□), the closed bars are patients who received oxaliplatin combination chemotherapy (■). The number of patients pooled in each group is indicated above each bar.